Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | BUB1 | O43683 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13482977 | 0.84 | EPHA2 (0.54) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL3321410 | 0.83 | SCN9A (0.48) | GPR119 | |
| SCHEMBL3321403 | 0.83 | SCN9A (0.48) | GPR119 | |
| SCHEMBL28851224 | 0.82 | EPHA2 (0.51) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL15058339 | 0.82 | EPHA2 (0.49) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL13482008 | 0.81 | EPHA2 (0.51) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL4510923 | 0.81 | EPHA2 (0.54) | PDK1EPHA2ERBB2EPHB4NR1H4 | |
| SCHEMBL8702864 | 0.79 | NR1H4 (0.49) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL8702860 | 0.79 | NR1H4 (0.49) | PDK1EPHA2ERBB2EPHB4BUB1 | |
| SCHEMBL8704689 | 0.79 | NR1H4 (0.49) | PDK1EPHA2ERBB2EPHB4BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |